Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers

Steady-state inhibitory activity of rofecoxib (Vioxx) on COX-2 versus COX-1 was compared with that of commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) in 76 healthy volunteers randomized to placebo, rofecoxib 12.5 mg qd, rofecoxib 25 mg qd, diclofenac 50 mg tid, ibuprofen 800 mg tid, sodium naproxen 550 mg bid, or meloxicam 15 mg qd. All of these doses include the high end of the approved clinical dose range. Ex vivo whole-blood assays were used to determine the effect on COX-2 and COX-1 activity, respectively. Urinary prostanoids were also measured. Mean inhibition of COX-2 (measured as the weighted average inhibition [WAI] of lipopolysaccharide [LPS]-induced PGE2 generation over 8 hours on day 6 vs. baseline) was -2.4%, 66.7%, 69.2%, 77.5%, 93.9%, 71.4%, and 71.5% for placebo, rofecoxib 12.5 mg, rofecoxib 25 mg, meloxicam, diclofenac, ibuprofen, and naproxen, respectively. Corresponding values for mean inhibition of COX-1 (measured as TXB2 generation in clotting whole blood) were -5.15%, 7.98%, 6.65%, 53.3%, 49.5%, 88.7%, and 94.9%. Rofecoxib had no significant effect on urinary excretion of 11-dehydro TXB2, a COX-1-derived product. These data support the contention that rofecoxib is the only drug of the regimens tested that uniquely inhibits COX-2 without affecting COX-1.

This article has been cited by other articles:

				M. D. M. Haag, M. J. Bos, A. Hofman, P. J. Koudstaal, M. M. B. Breteler, and B. H. C. Stricker Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke Arch Intern Med, June 9, 2008; 168(11): 1219 - 1224. [Abstract] [Full Text] [PDF]

				T P van Staa, L Smeeth, I Persson, J Parkinson, and H G M Leufkens What is the harm-benefit ratio of Cox-2 inhibitors? Int. J. Epidemiol., April 1, 2008; 37(2): 405 - 413. [Abstract] [Full Text] [PDF]

				C. H. Hennekens and S. Borzak Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 41 - 50. [Abstract] [PDF]

				J. C Waksman, A. Brody, and S. D Phillips Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe? Ann. Pharmacother., July 1, 2007; 41(7): 1163 - 1173. [Abstract] [Full Text] [PDF]

				S. Rohatagi, H. Kastrissios, Y. Gao, N. Zhang, J. Xu, J. Moberly, R. Wada, K. Yoshihara, M. Takahashi, K. Truitt, et al. Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX-2 Inhibitor J. Clin. Pharmacol., March 1, 2007; 47(3): 358 - 370. [Abstract] [Full Text] [PDF]

				M. Saudan, P. Saudan, T. Perneger, N. Riand, A. Keller, and P. Hoffmeyer Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: A PROSPECTIVE RANDOMISED TRIAL J Bone Joint Surg Br, February 1, 2007; 89-B(2): 155 - 159. [Abstract] [Full Text] [PDF]

				S. J. Hewett, J. M. Silakova, and J. A. Hewett Oral Treatment with Rofecoxib Reduces Hippocampal Excitotoxic Neurodegeneration J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1219 - 1224. [Abstract] [Full Text] [PDF]

				A Clayton and A J Knox COX-2: a link between airway inflammation and disordered chloride secretion in cystic fibrosis? Thorax, July 1, 2006; 61(7): 552 - 553. [Full Text] [PDF]

				M. SPINK, S. BAHN, and R. GLICKMAN Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks J Am Dent Assoc, October 1, 2005; 136(10): 1439 - 1448. [Abstract] [Full Text] [PDF]

				P. A. Konstantinopoulos and D. F. Lehmann The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding J. Clin. Pharmacol., July 1, 2005; 45(7): 742 - 750. [Abstract] [Full Text] [PDF]

				F. T. Shaya, S. W. Blume, C. M. Blanchette, M. R. Weir, and C. D. Mullins Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population Arch Intern Med, January 24, 2005; 165(2): 181 - 186. [Abstract] [Full Text] [PDF]

				C. M. Samama, R. Djoudi, T. Lecompte, N. Nathan-Denizot, J.-F. Schved, and the AFSSAPS Expert Group Perioperative platelet transfusion: recommendations of the Agence francaise de securite sanitaire des produits de sante (AFSSaPS) 2003: [Transfusion perioperatoire de plaquettes : recommandations de l'Agence francaise de securite sanitaire des produits de sante (AFSSaPS) 2003] Can J Anesth, January 1, 2005; 52(1): 30 - 37. [Abstract] [Full Text] [PDF]

				M. A. Buerkle, S. Lehrer, H.-Y. Sohn, P. Conzen, U. Pohl, and F. Krotz Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In Vivo Circulation, October 5, 2004; 110(14): 2053 - 2059. [Abstract] [Full Text] [PDF]

				P. Bogaty, J. M. Brophy, M. Noel, L. Boyer, S. Simard, F. Bertrand, and G. R. Dagenais Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study Circulation, August 24, 2004; 110(8): 934 - 939. [Abstract] [Full Text] [PDF]

				J. van Ryn, M. Kink-Eiband, I. Kuritsch, U. Feifel, G. Hanft, G. Wallenstein, G. Trummlitz, and M. Pairet Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers J. Clin. Pharmacol., July 1, 2004; 44(7): 777 - 784. [Abstract] [Full Text] [PDF]

				T. R. Hegi, T. Bombeli, B. Seifert, P. C. Baumann, U. Haller, M. P. Zalunardo, T. Pasch, and D. R. Spahn Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac Br. J. Anaesth., April 1, 2004; 92(4): 523 - 531. [Abstract] [Full Text] [PDF]

				H. Ma, J. Tang, P. F. White, A. Zaentz, R. H. Wender, A. Sloninsky, R. Naruse, R. Kariger, R. Quon, D. Wood, et al. Perioperative Rofecoxib Improves Early Recovery After Outpatient Herniorrhaphy Anesth. Analg., April 1, 2004; 98(4): 970 - 975. [Abstract] [Full Text] [PDF]

				B. Karamanlioglu, A. Turan, D. Memis, and M. Ture Preoperative Oral Rofecoxib Reduces Postoperative Pain and Tramadol Consumption in Patients After Abdominal Hysterectomy Anesth. Analg., April 1, 2004; 98(4): 1039 - 1043. [Abstract] [Full Text] [PDF]

				A. M. Blaicher, H. T. Landsteiner, O. Al-Falaki, J. Zwerina, I. Volf, D. Gruber, M. Zimpfer, and K. Hoerauf Acetylsalicylic Acid, Diclofenac, and Lornoxicam, but Not Rofecoxib, Affect Platelet CD 62 Expression Anesth. Analg., April 1, 2004; 98(4): 1082 - 1085. [Abstract] [Full Text] [PDF]

				M. L. Capone, S. Tacconelli, M. G. Sciulli, M. Grana, E. Ricciotti, P. Minuz, P. Di Gregorio, G. Merciaro, C. Patrono, and P. Patrignani Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects Circulation, March 30, 2004; 109(12): 1468 - 1471. [Abstract] [Full Text] [PDF]

				P. A. Howard and P. Delafontaine Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk J. Am. Coll. Cardiol., February 18, 2004; 43(4): 519 - 525. [Abstract] [Full Text] [PDF]

				L. M. Title, K. Giddens, M. M. McInerney, M. J. McQueen, and B. A. Nassar Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1747 - 1753. [Abstract] [Full Text] [PDF]

				D. Layton, E. Heeley, K. Hughes, and S. A. W. Shakir Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data Rheumatology, November 1, 2003; 42(11): 1342 - 1353. [Abstract] [Full Text] [PDF]

				E.A.J. Knijff-Dutmer, J. Van der Palen, G. Schut, and M.A.F.J. Van de Laar The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users QJM, July 1, 2003; 96(7): 513 - 520. [Abstract] [Full Text] [PDF]

				H. S. Smith and W. Baird Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population American Journal of Hospice and Palliative Medicine, July 1, 2003; 20(4): 297 - 306. [Abstract] [PDF]

				A. Dallob, C. J. Hawkey, H. Greenberg, N. Wight, P. De Schepper, S. Waldman, P. Wong, L. DeTora, B. Gertz, N. Agrawal, et al. Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor J. Clin. Pharmacol., June 1, 2003; 43(6): 573 - 585. [Abstract] [Full Text] [PDF]

				E. Tuleja, F. Mejza, A. Cmiel, and A. Szczeklik Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1111 - 1115. [Abstract] [Full Text] [PDF]

				M. Mamdani, P. Rochon, D. N. Juurlink, G. M. Anderson, A. Kopp, G. Naglie, P. C. Austin, and A. Laupacis Effect of Selective Cyclooxygenase 2 Inhibitors and Naproxen on Short-term Risk of Acute Myocardial Infarction in the Elderly Arch Intern Med, February 24, 2003; 163(4): 481 - 486. [Abstract] [Full Text] [PDF]

				E. A. Knijff-Dutmer, G. A Schut, and M. A. van de Laar Concomitant Coumarin-NSAID Therapy and Risk for Bleeding Ann. Pharmacother., January 1, 2003; 37(1): 12 - 16. [Abstract] [Full Text] [PDF]

				A. Turan, S. Emet, B. Karamanlioglu, D. Memis, N. Turan, and Z. Pamukcu Analgesic Effects of Rofecoxib in Ear-Nose-Throat Surgery Anesth. Analg., November 1, 2002; 95(5): 1308 - 1311. [Abstract] [Full Text] [PDF]

				J. E. Dalen Selective COX-2 Inhibitors, NSAIDs, Aspirin, and Myocardial Infarction Arch Intern Med, May 27, 2002; 162(10): 1091 - 1092. [Full Text] [PDF]

				D. J. Watson, T. Rhodes, B. Cai, and H. A. Guess Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis Arch Intern Med, May 27, 2002; 162(10): 1105 - 1110. [Abstract] [Full Text] [PDF]

				E. Rahme, L. Pilote, and J. LeLorier Association Between Naproxen Use and Protection Against Acute Myocardial Infarction Arch Intern Med, May 27, 2002; 162(10): 1111 - 1115. [Abstract] [Full Text] [PDF]

				F. Catella-Lawson, M. P. Reilly, S. C. Kapoor, A. J. Cucchiara, S. DeMarco, B. Tournier, S. N. Vyas, and G. A. FitzGerald Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin N. Engl. J. Med., December 20, 2001; 345(25): 1809 - 1817. [Abstract] [Full Text] [PDF]

				T. G. Burnakis, M. Fleming, M. A. Konstam, L. A. Demopoulos, K. D. Grant, E. J. Haldey, M. Pappagallo, M. Minic, P. L. McGeer, E. G. McGeer, et al. Cardiovascular Events and COX-2 Inhibitors JAMA, December 12, 2001; 286(22): 2808 - 2813. [Full Text] [PDF]

				D. Mukherjee, S. E. Nissen, and E. J. Topol Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors JAMA, August 22, 2001; 286(8): 954 - 959. [Abstract] [Full Text] [PDF]

				G. A. FitzGerald and C. Patrono The Coxibs, Selective Inhibitors of Cyclooxygenase-2 N. Engl. J. Med., August 9, 2001; 345(6): 433 - 442. [Full Text] [PDF]

				C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M. B. Ferraz, C. J. Hawkey, M. C. Hochberg, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis N. Engl. J. Med., November 23, 2000; 343(21): 1520 - 1528. [Abstract] [Full Text] [PDF]

				M. A. Konstam, M. R. Weir, A. Reicin, D. Shapiro, R. S. Sperling, E. Barr, and B. J. Gertz Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Circulation, November 6, 2001; 104(19): 2280 - 2288. [Abstract] [Full Text] [PDF]